Protagonist Therapeutics, Inc. (PTGX) Financial Ratios
12 years of historical data (2014–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 9.56
30Y Low9.6·High9.6
P/FCF
↑
113.36
↑+101% vs avg
5yr avg: 56.38
30Y Low13.7·High114.8
P/B Ratio
↑
10.22
↑+110% vs avg
5yr avg: 4.88
30Y Low2.3·High9.0
ROE
↑
-20.2%
-16% vs avg
5yr avg: -17.4%
30Y Low-169%·High54%
Debt/EBITDA
N/A
—
5yr avg: 0.04
30Y Low0.0·High0.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PTGX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Protagonist Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 113.4x P/FCF, 101% above the 5-year average of 56.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.4B | $5.6B | $2.5B | $1.3B | $535M | $1.6B | $693M | $183M | $151M | $368M | $143M |
| Enterprise Value | $6.2B | $5.4B | $2.4B | $1.1B | $413M | $1.5B | $582M | $167M | $68M | $262M | $122M |
| P/E Ratio → | -48.22 | — | 9.13 | — | — | — | — | — | — | — | — |
| P/S Ratio | 138.15 | 120.66 | 5.78 | 21.69 | 20.13 | 57.91 | 24.22 | 790.27 | 4.87 | 18.34 | — |
| P/B Ratio | 10.22 | 9.03 | 3.72 | 3.87 | 2.48 | 5.28 | 2.48 | 2.28 | — | — | — |
| P/FCF | 113.36 | 99.01 | 13.74 | — | — | — | — | — | — | 114.80 | — |
| P/OCF | 110.23 | 96.28 | 13.64 | — | — | — | — | — | — | 95.05 | — |
P/E links to full P/E history page with 30-year chart
PTGX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 118.10 | 5.58 | 18.60 | 15.54 | 53.60 | 20.33 | 721.03 | 2.21 | 13.06 | — |
| EV / EBITDA | — | — | 9.56 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 9.59 | — | — | — | — | — | — | — | — |
| EV / FCF | — | 96.90 | 13.27 | — | — | — | — | — | — | 81.73 | — |
PTGX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Protagonist Therapeutics, Inc. earns an operating margin of -343.6%. Operating margins have compressed from -156.1% to -343.6% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -20.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.3% | 97.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -343.6% | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% | — |
| Net Profit Margin | -282.8% | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -20.2% | -20.2% | 54.4% | -28.6% | -49.4% | -43.3% | -36.8% | -96.5% | — | — | — |
| ROA | -18.4% | -18.4% | 49.9% | -26.1% | -42.8% | -37.4% | -27.6% | -52.4% | -25.7% | -28.7% | -68.3% |
| ROIC | -21.8% | -21.8% | 51.3% | -57.4% | -71.5% | -53.9% | -41.7% | -94.4% | — | — | — |
| ROCE | -23.9% | -23.9% | 48.9% | -33.8% | -50.5% | -42.8% | -32.0% | -69.2% | -36.1% | -36.3% | -65.8% |
PTGX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $128M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.00 | 0.02 | 0.02 | 0.02 | 0.21 | — | — | — |
| Debt / EBITDA | — | — | 0.04 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.19 | -0.13 | -0.55 | -0.57 | -0.39 | -0.40 | -0.20 | — | — | — |
| Net Debt / EBITDA | — | — | -0.34 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.11 | -0.47 | — | — | — | — | — | — | -33.07 | — |
| Interest Coverage | — | — | — | — | — | — | -107.89 | -459.82 | — | — | — |
Net cash position: cash ($128M) exceeds total debt ($10M)
PTGX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Protagonist Therapeutics, Inc.'s current ratio of 12.71x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 16.71x to 12.71x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.71 | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.26 | 3.55 | 12.94 |
| Quick Ratio | 12.71 | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.17 | 3.75 | 14.13 |
| Cash Ratio | 12.49 | 12.49 | 8.84 | 16.06 | 7.61 | 7.43 | 7.60 | 3.76 | 4.93 | 3.38 | 12.06 |
| Asset Turnover | — | 0.07 | 0.58 | 0.17 | 0.11 | 0.08 | 0.09 | 0.00 | 0.22 | 0.12 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 35.66 | 141.56 | 62.85 | 0.71 | 71.15 | 48.72 | 10673.48 | 54.14 | 33.04 | — |
PTGX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Protagonist Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 11.0% | — | — | — | — | — | — | — | — |
| FCF Yield | 0.9% | 1.0% | 7.3% | — | — | — | — | — | — | 0.9% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $64M | $65M | $57M | $49M | $46M | $34M | $26M | $22M | $18M | $7M |
Peer Comparison
Compare PTGX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PTGXYou | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 ARDX | $2B | -26.8 | — | — | 89.5% | -10.1% | -36.2% | -10.7% | — |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See PTGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTGX vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonPTGX — Frequently Asked Questions
Quick answers to the most common questions about buying PTGX stock.
What is Protagonist Therapeutics, Inc.'s P/E ratio?
Protagonist Therapeutics, Inc.'s current P/E ratio is -48.2x. The historical average is 9.1x.
What is Protagonist Therapeutics, Inc.'s ROE?
Protagonist Therapeutics, Inc.'s return on equity (ROE) is -20.2%. The historical average is -58.8%.
Is PTGX stock overvalued?
Based on historical data, Protagonist Therapeutics, Inc. is trading at a P/E of -48.2x. Compare with industry peers and growth rates for a complete picture.
What are Protagonist Therapeutics, Inc.'s profit margins?
Protagonist Therapeutics, Inc. has 97.3% gross margin and -343.6% operating margin.